Making it work Feedback reports and prescribing changes as a Medicaid drug initiative moves ahead

6. Of the other 712 prescribers, for at least one therapeutic class: * 29% improved both generic and DAW * 54% improved generic only * 45% improved DAW  * 18% had no change In the best practice group (top quartile)  *47% improved both generic and DAW  *85% improved generic only *49% improved DAW  *13% had no change. 

13. Adult generics and safety first: The criteria for generic first* Use of another brand name atypical antipsychotic is actually a documented) continuation therapy of what is a currently stable regimen (i.e. in claims and other sources) There has been a past trial of risperidone that resulted in discontinuation due to side effects (e.g. per client�s recollection) There has been a past trial of risperidone that resulted in discontinuation due to lack of benefits (e.g. noted in a claim or clinical record) There is a history of hyper-prolatinemia or EPS (e.g. dystonic reaction, akathesia, parkinsonism) When there are FDA indications not covered by risperidone or another generic (e.g. Bipolar with acute depression) Person requests another drug or refuses risperidone and it is documented in the clinical record (*) EPA Criteria will require good documentation in retrospective payment review

14. Adult generics and safety first FAQ Can I get an emergency fill  Yes Can I get what I need in a crisis Yes -- by writing on the script �Adult in Crisis� or �from the generic first criteria� Can I use samples as refill protections No. Why use samples if HRSA pays for all drugs without co-pays, and why dispense a sample to a Medicaid client when the script is non-transparent to other prescribers, ERs and hospitals? Can I continue on my existing meds? Yes. These are not considered new starts